The Microbiome-Peptide Axis: Gut Bugs and Hormones
Microbiome and Peptide Biology
3 Bidirectional Pathways
The microbiome-peptide axis operates through three overlapping channels: antimicrobial peptides that shape bacterial composition, bacterial metabolites that trigger peptide hormone release, and neuropeptide signaling that connects gut bacteria to the brain.
Khan et al., Molecular and Cellular Endocrinology, 2025
Khan et al., Molecular and Cellular Endocrinology, 2025
View as imageThe relationship between your gut bacteria and your peptide hormones is not one-directional. Bacteria produce metabolites that trigger peptide hormone release from enteroendocrine cells. Simultaneously, the host produces antimicrobial peptides that determine which bacteria survive in the gut. And neuropeptides carry signals from this bacterial-hormonal interplay to the brain, influencing appetite, mood, and immune function. Khan et al.'s 2025 review in Molecular and Cellular Endocrinology mapped this complete system, documenting how intestinal microbiota, the immune system, and hormones interact to create what researchers now call the microbiome-peptide axis.[1]
This axis is not a metaphor. It operates through specific molecular mechanisms: defensins secreted by Paneth cells that selectively kill certain bacterial species while sparing others, short-chain fatty acids produced by bacterial fiber fermentation that bind FFAR2/FFAR3 receptors on L-cells to trigger GLP-1 release, and cathelicidin LL-37 that modulates both bacterial communities and neuroinflammatory signaling in the gut-brain axis. Each of these pathways has been characterized at the molecular level, and disruption of any one of them produces measurable changes in both microbiome composition and peptide hormone profiles.
For the specific SCFA-to-hormone pathway, see Short-Chain Fatty Acids and Peptide Hormone Release: The Bacterial Connection.
Key Takeaways
- The microbiome-peptide axis operates through three bidirectional pathways: host antimicrobial peptides shaping bacterial composition, bacterial metabolites triggering peptide hormone release, and neuropeptide signaling connecting gut bacteria to the brain (Khan et al., Molecular and Cellular Endocrinology, 2025)
- Alpha-defensin 1 induction via AhR activation reversed gut microbiota dysbiosis and colitis in a 2025 study, demonstrating that host antimicrobial peptides can therapeutically reshape the microbiome (Palrasu et al., Gut Microbes, 2025)
- Human defensin HD5 modulates Bifidobacterium populations during weaning, with effects persisting into later life, showing that early AMP-microbiome interactions shape long-term gut composition (Shimizu et al., Communications Medicine, 2025)
- Cathelicidin LL-37 has immunomodulatory effects in the gut-brain axis, linking mucosal immunity to neuroinflammation through a novel peptide-mediated pathway (Nourizadeh et al., Experimental Physiology, 2026)
- Paneth cell alpha-defensin misfolding correlates with dysbiosis and ileitis in Crohn's disease models, demonstrating that dysfunctional AMP production directly drives pathological microbiome shifts (Shimizu et al., Life Science Alliance, 2020)
- Aging impairs intestinal antimicrobial peptide responses and worsens fecal microbiome dysbiosis, suggesting the microbiome-peptide axis deteriorates with age (Wheatley et al., Shock, 2020)
Pathway 1: Host Antimicrobial Peptides Shape the Microbiome
The human gut produces antimicrobial peptides (AMPs) that act as selective filters on the bacterial community. This is not indiscriminate killing; it is curated selection. Different AMPs have different spectra of activity, and the combination of AMPs produced at any given intestinal location determines which bacteria can colonize and persist there.
Paneth Cells and Alpha-Defensins
Paneth cells, located at the base of small intestinal crypts, secrete alpha-defensins (HD5 and HD6 in humans) directly into the intestinal lumen. These cationic peptides create an antimicrobial gradient that is highest near the crypt base and diminishes toward the villus tip. The gradient protects stem cells at the crypt base while allowing controlled bacterial interaction with the epithelial surface above.
A 2025 study by Shimizu et al. demonstrated that human defensin HD5 modulates Bifidobacterium populations during the weaning period, and that this early-life interaction shapes Bifidobacterium abundance into later life.[2] This finding connects a specific host AMP to a specific bacterial genus across a developmental timeline, demonstrating that the peptides you produce as an infant influence which bacteria you carry as an adult.
When alpha-defensin production fails, the consequences are measurable. Shimizu et al. showed in 2020 that Paneth cell alpha-defensin misfolding correlates with dysbiosis and ileitis in Crohn's disease mouse models.[3] The mechanism is direct: misfolded defensins lose their antimicrobial selectivity, allowing pathogenic bacteria to expand while beneficial species decline. Zhang et al. confirmed the importance of Paneth cells in 2026 by showing that VGLL4 modulates Paneth cell function and is required to sustain intestinal homeostasis.[4]
Fu et al.'s 2023 review in Signal Transduction and Targeted Therapy provided a comprehensive map of defensin mechanisms and regulation in host defense, documenting how defensin production responds to bacterial signals, dietary components, and inflammatory mediators in a continuous feedback loop.[5]
For more on how defensins work, see How Your Gut Bacteria Produce Antimicrobial Peptides.
Cathelicidin LL-37: More Than an Antibiotic
LL-37, the only human cathelicidin, functions as both an antimicrobial peptide and an immunomodulatory signal. In the gut, LL-37 kills bacteria through membrane disruption (like defensins), but it also activates formyl peptide receptor 2 (FPR2), modulates toll-like receptor signaling, and recruits immune cells to sites of bacterial breach.
Fabisiak et al.'s 2016 review described LL-37 as a "cathelicidin-related antimicrobial peptide with pleiotropic activity," emphasizing that its immunomodulatory functions may be as important as its direct antimicrobial effects for maintaining gut homeostasis.[6] A 2026 study by Nourizadeh et al. extended this further, identifying immunomodulatory effects of cathelicidin in the gut-brain axis that link mucosal immunity to neuroinflammation through a peptide-mediated pathway.[7]
For deeper coverage of LL-37's gut role, see LL-37 in the Gut: How Your Body's Natural Antibiotic Protects Your Intestines.
Therapeutic Implications: Reshaping the Microbiome with AMPs
A 2025 study demonstrated that activating the aryl hydrocarbon receptor (AhR) transcriptionally induces alpha-defensin 1, which reversed gut microbiota dysbiosis and colitis.[8] This is a proof-of-concept that host AMP production can be pharmacologically enhanced to therapeutically reshape the microbiome, using the body's own peptide defense system rather than exogenous antibiotics or probiotics.
For how AMPs balance protection with microbiome preservation, see Antimicrobial Peptides and Microbiome Balance: Protection Without Destruction.
Pathway 2: Bacterial Metabolites Drive Peptide Hormone Release
The reverse direction of the axis is equally well-characterized: gut bacteria produce metabolites that directly trigger peptide hormone secretion from enteroendocrine cells.
SCFAs and the FFAR2/FFAR3 System
Short-chain fatty acids (acetate, propionate, butyrate) produced by bacterial fermentation of dietary fiber bind to FFAR2 (GPR43) and FFAR3 (GPR41) receptors on enteroendocrine L-cells, triggering the release of GLP-1, PYY, and GLP-2. This pathway was definitively established by Tolhurst et al. in 2012 and has been confirmed by dozens of subsequent studies.
The clinical relevance is direct: GLP-1 is the target of semaglutide, tirzepatide, and other blockbuster metabolic drugs. Bacterial SCFA production provides a natural, microbiome-dependent mechanism for endogenous GLP-1 release. Ganamurali et al.'s 2026 review documented that this relationship is bidirectional: GLP-1 receptor agonist drugs themselves alter microbiome composition, which changes SCFA production, which modifies endogenous GLP-1 secretion.[9]
Beyond SCFAs: Other Bacterial Metabolites
SCFAs are the most studied bacterial metabolites that affect peptide signaling, but they are not the only ones. Bacteria produce tryptophan metabolites (indole, indole-3-propionic acid, tryptamine) that activate the aryl hydrocarbon receptor (AhR) on epithelial cells, influencing both AMP production and enteroendocrine cell function. Secondary bile acids produced by bacterial biotransformation of host bile acids activate the TGR5 receptor on L-cells, triggering GLP-1 release through a pathway independent of SCFAs. Bacterial-derived gamma-aminobutyric acid (GABA), produced by certain Lactobacillus and Bifidobacterium species, acts on GABA receptors in the enteric nervous system, modulating gut motility and peptide hormone secretion patterns.
The diversity of bacterial metabolites affecting peptide signaling means that microbiome composition influences the host peptide hormone profile through multiple parallel channels. Changes in one bacterial species can shift several metabolite pathways simultaneously, producing coordinated hormonal effects that are difficult to attribute to any single mechanism.
Gut Hormone Integration
The peptide hormones triggered by bacterial metabolites do not act independently. Steinert et al.'s 2017 review in Physiological Reviews described how ghrelin, CCK, GLP-1, and PYY form an integrated hormonal network where bacterial input through SCFAs influences the entire system simultaneously.[10] Lansbury et al. identified vagal neurons in the right nodose ganglion that co-express receptors for GLP-1, CCK, and PYY, providing a neural convergence point where multiple bacteria-triggered peptide signals are integrated before transmission to the brain.[11]
Specific Bacteria, Specific Hormones
Vishwakarma et al.'s 2025 review of the gut microbiome in obesity described how specific bacterial species produce metabolites that differentially affect appetite-regulating peptides.[12] Faecalibacterium prausnitzii drives butyrate-GPR43-GLP-1 signaling. Bifidobacterium species produce acetate that promotes both GLP-1 and PYY release. Lactobacillus species produce bacteriocins, antimicrobial peptides in their own right, that reshape the microbial community and indirectly affect host hormone production.[13]
For how probiotics specifically boost peptide production, see Can Probiotics Boost Your Body's Peptide Production?.
Pathway 3: Neuropeptide Signaling and the Gut-Brain Axis
The third pathway connects gut bacteria to the brain through neuropeptide signaling. This is the gut-brain axis in its peptide dimension.
The Enteric Nervous System
The enteric nervous system (ENS) contains over 500 million neurons distributed throughout the gastrointestinal tract. These neurons produce neuropeptides (substance P, vasoactive intestinal peptide, neuropeptide Y, calcitonin gene-related peptide) that regulate motility, secretion, blood flow, and immune function locally. Tao et al.'s 2025 review documented how microbiota and enteric nervous system crosstalk operates in diabetic gastroenteropathy, showing that bacterial signals directly influence ENS neuropeptide production and that disrupted crosstalk contributes to the gastroparesis and intestinal dysmotility seen in diabetes.[14]
The neuropeptides produced by the ENS serve dual functions. Substance P and neuropeptide Y have documented antimicrobial activity against certain bacterial species, meaning the nervous system itself contributes to microbiome shaping. Simultaneously, bacterial metabolites (SCFAs, tryptophan derivatives, bile acid modifications) activate enteric neurons and alter their neuropeptide output. The result is a local neural circuit in the gut wall where bacteria influence nerve signaling and nerve signaling influences bacterial survival, creating a fast-acting regulatory loop that operates independently of central nervous system input.
The Enterolimbic Connection
Bacterial metabolites and peptide hormones converge on vagal afferent neurons that project to the nucleus tractus solitarius (NTS) in the brainstem, which relays signals to the hypothalamus and limbic system. This vagal pathway carries integrated information about bacterial composition (encoded through metabolite-triggered peptide release) to brain regions that regulate appetite, mood, and stress responses.
The vagus nerve is not a passive conduit. It contains approximately 80% afferent (gut-to-brain) fibers and only 20% efferent (brain-to-gut) fibers, making it primarily a sensory system that reports gut conditions to the brain. The peptide hormones GLP-1, PYY, and CCK activate specific vagal afferent subtypes, and the pattern of activation encodes information about the nutritional and microbial state of the gut. Vagotomy (surgical cutting of the vagus nerve) eliminates many of the central effects of peripherally produced gut peptides, confirming the vagus as the primary communication channel.
Nourizadeh et al.'s 2026 study on cathelicidin's immunomodulatory effects in the gut-brain axis identified a novel link between mucosal immunity and neuroinflammation, mediated by LL-37's ability to simultaneously modulate bacterial communities and immune-neural signaling.[7] This dual function makes LL-37 a molecular bridge between the microbiome and the nervous system. When gut barrier function is compromised (as in dysbiosis or inflammatory bowel disease), LL-37 production changes, bacterial translocation increases, and neuroinflammatory signaling amplifies, potentially contributing to the mood and cognitive symptoms frequently reported in gut disorders.
For related articles on LL-37's immunomodulatory properties, see LL-37's Dual Role: Anti-Inflammatory and Pro-Inflammatory Effects and Vitamin D and LL-37: Why Sunlight Boosts Your Antimicrobial Peptides.
When the Axis Breaks: Disease States
Aging
Wheatley et al. demonstrated in 2020 that advanced age impairs intestinal antimicrobial peptide responses and worsens fecal microbiome dysbiosis following burn injury in mice.[15] The finding suggests that age-related decline in AMP production creates a permissive environment for dysbiosis, which in turn alters bacterial metabolite production and peptide hormone signaling. The microbiome-peptide axis may deteriorate as a system rather than failing at a single point. This systemic decline could explain why elderly individuals show simultaneously increased susceptibility to gut infections, altered appetite regulation, and reduced metabolic flexibility: all are downstream consequences of a degraded axis.
Inflammatory Bowel Disease
Crohn's disease provides the clearest example of axis dysfunction. Paneth cell defensin misfolding allows pathogenic bacterial expansion, which drives inflammation, which further damages Paneth cells, creating a self-reinforcing cycle of AMP failure and dysbiosis.[3] Therapeutic strategies targeting defensin production or AMP supplementation aim to break this cycle by restoring the host side of the axis.
Metabolic Disease
Obesity and type 2 diabetes are associated with altered microbiome composition, reduced SCFA production, decreased GLP-1 and PYY secretion, and elevated ghrelin signaling. Each of these changes maps to a specific node in the microbiome-peptide axis. Whether dysbiosis causes metabolic peptide hormone dysfunction or metabolic disease drives dysbiosis remains contested; the most likely answer is both, operating as a bidirectional feedback system.
The practical consequence is that interventions targeting one node may fail if other nodes remain dysfunctional. A prebiotic supplement that increases SCFA-producing bacteria will have limited effect if the recipient's L-cells are producing insufficient FFAR2 receptors (which can occur in chronic inflammation). A GLP-1 receptor agonist drug will alter microbiome composition, but the direction and magnitude of change depend on the patient's baseline microbiome. The axis framework argues for multi-target approaches: combining dietary fiber (to boost SCFA production), probiotics (to supply specific SCFA-producing species), and potentially AMP-inducing compounds (to reshape the microbiome from the host side) rather than relying on any single intervention.
Antibiotic Disruption
Antibiotic treatment provides a natural experiment in axis disruption. Broad-spectrum antibiotics simultaneously reduce SCFA-producing bacteria (decreasing peptide hormone release) and kill bacteria that contribute to AMP regulation (disrupting the host defense feedback). Post-antibiotic microbiome recovery can take months, and the peptide hormone profiles during this period are characteristically altered: reduced GLP-1 and PYY, increased susceptibility to Clostridioides difficile (normally suppressed by AMP-maintained microbial competition), and altered neuropeptide signaling that may contribute to post-antibiotic gastrointestinal symptoms.
The Diagnostic and Therapeutic Frontier
Understanding the microbiome-peptide axis opens two clinical directions.
Diagnostic Applications
Microbiome peptide profiling could reveal disruptions in AMP production, bacterial metabolite generation, or neuropeptide signaling before clinical disease manifests. By measuring fecal defensin levels, SCFA profiles, and circulating peptide hormone concentrations simultaneously, clinicians could identify which node of the axis is dysfunctional in a given patient. A patient with normal defensin levels but low SCFAs likely has a dietary fiber deficit or a microbiome depleted of fermentative species. A patient with adequate SCFAs but low GLP-1 may have L-cell dysfunction or insufficient FFAR2 expression. The axis model enables differential diagnosis that single-biomarker approaches cannot provide. For this emerging approach, see Microbiome Peptide Profiling: A New Diagnostic Frontier.
Therapeutic Strategies
Interventions could target any node of the axis: prebiotics to increase SCFA-producing bacteria and boost peptide hormone release; specific probiotic strains (like Bifidobacterium breve or Faecalibacterium prausnitzii) that enhance endogenous GLP-1 production through validated SCFA pathways; AhR agonists or vitamin D supplementation to increase host defensin and cathelicidin production, thereby reshaping the microbiome from the host side; or recombinant AMPs delivered directly to the gut to correct dysbiosis without broad-spectrum antibiotic collateral damage.
The axis framework argues that single-target interventions may be less effective than combinatorial approaches. A prebiotic paired with a probiotic targets both the substrate and the bacterium. Adding vitamin D targets the host AMP side simultaneously. The most effective interventions are likely those that address the axis as a system rather than treating bacteria, peptides, or hormones in isolation.
Current evidence for these combinatorial approaches is largely theoretical, extrapolated from single-pathway studies. No clinical trial has directly tested a multi-node intervention strategy designed around the microbiome-peptide axis model. This gap represents both the limitation and the opportunity of the axis concept: the framework is well-supported by mechanistic evidence, but its clinical utility remains to be proven through appropriately designed trials.
For related content on how antimicrobial peptides compare to conventional antibiotics for microbiome management, see Antimicrobial Peptides as Alternatives to Antibiotics: Can They Solve Resistance?.
The Bottom Line
The microbiome-peptide axis operates through three bidirectional pathways. Host antimicrobial peptides (defensins, cathelicidins) selectively shape which bacteria colonize the gut. Bacterial metabolites (primarily SCFAs) trigger peptide hormone release (GLP-1, PYY, serotonin) from enteroendocrine cells. Neuropeptides relay the integrated output to the brain via vagal afferents. Disruption at any node (aging, IBD, metabolic disease) produces cascading effects across the system. The therapeutic potential lies in targeting multiple axis nodes simultaneously rather than treating any single pathway in isolation.